VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

Conference call to take place Wednesday, November 13, 2019 at 8:30 am Eastern time

News provided by

Nov 07, 2019, 08:30 ET

AUSTIN, Texas, Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providing a business update.

Event: VolitionRx Limited Third Quarter 2019 Earnings and Business Update Conference Call
Date: Wednesday, November 13, 2019
Time: 8:30 a.m. Eastern time
U.S. & Canada Dial-in: 1-877 407 9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201 493 6779
Conference ID: 13696533

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition's activities, including details of new and ongoing clinical trials, important events that have taken place in the third quarter of 2019, and milestones for the remainder of 2019 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until November 27, 2019. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13696533.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics^TM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a majority-owned subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Nucleosomics^TM is a trademark of Volition and its subsidiaries.

For more information about Volition, visit Volition's website (http://www.volition.com) or connect with us via:

Twitter: https://twitter.com/volitionRx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media/Investor Contacts

Louise Batchelor, Volition

[email protected]

+44 (0)7557 774620

Scott Powell, Volition

[email protected]

+1 (646) 650 1351

Joseph Green, Edison Advisors

[email protected]

+1 (646) 653 7030

SOURCE VolitionRx Ltd